Agenus Announces Appointment of Tom Harrison to Board of Directors
August 08 2024 - 7:00AM
Business Wire
Advertising Veteran Tapped to Elevate Awareness
of Agenus and Its Innovative Pipeline
Agenus Inc. (NASDAQ: AGEN), a leader in discovering and
developing novel immunological agents to treat various cancers,
today announced the appointment of Tom Harrison to its Board of
Directors. Mr. Harrison brings a wealth of experience and a proven
track record in healthcare advertising, branding, and strategic
advising.
Tom Harrison's Background Highlights:
- Chairman Emeritus of Diversified Agency Services (DAS),
Omnicom Group Inc.: Harrison led the world's largest group of
marketing services companies, overseeing an unparalleled range of
services including public relations, crisis management, branding,
and healthcare advertising. Under his leadership, DAS grew to
become the largest division within Omnicom Group, generating annual
revenues of over $6 billion.
- Experience in Leading Marketing Services Companies:
Harrison's tenure at DAS saw the division expand to over 5,000
worldwide clients, accounting for more than 50% of Omnicom's total
revenues. He acquired and led a group of companies that became
influential in their respective disciplines.
- Proven Track Record in Healthcare Advertising: Before
joining Omnicom, Harrison co-founded Harrison & Star Business
Group, which became the most successful and rapidly growing agency
in the healthcare industry. His unique approach fused high science
with high creativity, positioning the agency as a leader in the
market.
- Senior Operating Partner at Merida Capital Partners: In
his current role, Harrison focuses on strategic and operational
advising across Merida's portfolio companies, contributing his
expertise to the dynamic cannabis industry.
In addition to his role at Merida Capital Partners, Mr. Harrison
serves on the boards of AFC Gamma and Acurx Pharmaceuticals.
“We are thrilled to welcome Tom Harrison to our Board of
Directors,” said Garo Armen, PhD, Chairman and CEO of Agenus.
“Tom’s extensive experience in healthcare advertising and strategic
advising, combined with his proven leadership skills, will be
invaluable as we continue to advance our mission of harnessing the
power of the immune system to bring innovative therapies to
patients.”
Educating the World About Agenus and Our Pipeline
As Agenus continues to develop its robust pipeline of novel
immunotherapy candidates, the importance of effectively
communicating our scientific advancements and therapeutic potential
to a global audience cannot be overstated. Tom Harrison’s
background in leading large-scale marketing and communications
efforts uniquely positions him to drive these initiatives
forward.
Harrison's experience in healthcare advertising and branding
will be instrumental in elevating Agenus' visibility and reputation
within the scientific and medical communities. His ability to
convey complex scientific concepts in an accessible and compelling
manner will help educate stakeholders, including healthcare
providers, patients, investors, and regulatory bodies, about the
groundbreaking work being conducted at Agenus.
“Tom’s expertise in strategic communications and his deep
understanding of the healthcare landscape will play a critical role
in our efforts to educate the world about Agenus’ innovative
pipeline,” added Dr. Armen. “His leadership will be crucial as we
strive to enhance awareness and understanding of our mission to
improve patient outcomes through cutting-edge immunotherapies.”
About Agenus
Agenus is a leading immuno-oncology company targeting cancer
with a comprehensive pipeline of immunological agents. The company
was founded in 1994 with a mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus has robust end-to-end development
capabilities, across commercial and clinical cGMP manufacturing
facilities, research and discovery, and a global clinical
operations footprint. Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding its botensilimab
and balstilimab programs, expected regulatory timelines and
filings, and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"forecasts," "estimates," "will," “establish,” “potential,”
“superiority,” “best in class,” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Annual Report on
Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240808315840/en/
Investors 917-362-1370 investor@agenusbio.com
Media 612-839-6748 communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024